StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
13
This year
1
Publishing Date
2024 - 01 - 29
1
2023 - 12 - 12
1
2023 - 05 - 25
1
2023 - 02 - 16
1
2022 - 12 - 07
1
2022 - 11 - 08
1
2022 - 08 - 15
1
2022 - 05 - 05
1
2022 - 04 - 13
1
2022 - 01 - 17
1
2021 - 12 - 09
1
2021 - 11 - 30
1
2021 - 11 - 18
1
Sector
Health technology
13
Tags
Agreement
11
Alliances
24
America
28
Antibody
19
Astrazeneca
15
Biotech
28
Breast
11
Breast cancer
13
Cancer
144
Cell
14
Clinical-trials-phase-iii
16
Collaboration
14
Covid-19
8
Diabetes
16
Diagnostic
10
Diagnostics
11
Disease
34
Drug
70
Drug delivery
12
Enhertu
24
Europe
11
Expected
13
Fda
9
Financial
10
Financial results
9
Global
108
Granted
8
Growing
24
Growth
120
Health
9
Her2
27
Her2-
18
Immunotherapy
10
Iot
8
Key
9
License
16
Liver
18
Lung
24
Lung cancer
10
Market
267
Metastatic breast cancer
11
N/a
516
Partnership
8
People
10
Pharma
10
Positive
13
Reach
20
Report
95
Research
73
Respiratory
12
Results
30
Review
11
Set
16
System
9
Technology
10
Therapeutics
71
Therapy
32
Treatment
46
Trial
52
Vaccine
29
Entities
Artelo biosciences, inc.
1
Astrazeneca plc
13
Avenue therapeutics, inc.
1
Fortress biotech, inc.
2
Genprex, inc.
1
Icosavax inc
1
Symbols
ABBV
31
ADIL
10
ALNY
19
ALPMF
14
ALPMY
14
AMGN
14
ANVS
10
AQST
18
ARVL
21
AZN
13
BBIO
16
BGNE
19
BIIB
13
BMY
27
BNTX
17
BYSI
11
CHRS
21
CLDX
10
CLSD
15
DARE
13
FBIO
10
FNCTF
21
GILD
13
GSK
12
HOTH
14
IMMP
11
IMMX
10
INCY
15
IONS
21
IT
12
JNJ
46
LLY
30
LTUM
14
MDWD
11
MRK
19
MS
10
MYOV
10
NDAQ
42
NVS
19
NVSEF
15
PFE
45
PLRX
10
PPRUF
11
PPRUY
11
RCKT
11
RDHL
10
REGN
26
RGNX
17
RNAZ
10
SCYX
11
SLS
11
SNY
103
SNYNF
79
SRNE
19
TAK
15
TAYD
17
TEVJF
14
TNXP
12
VERU
10
VRTX
11
Exchanges
Nasdaq
13
Crawled Date
2024 - 01 - 29
1
2023 - 12 - 12
1
2023 - 05 - 25
1
2023 - 02 - 16
1
2022 - 12 - 07
1
2022 - 11 - 08
1
2022 - 08 - 15
1
2022 - 05 - 05
1
2022 - 04 - 13
1
2022 - 01 - 17
1
2021 - 12 - 09
1
2021 - 11 - 30
1
2021 - 11 - 18
1
Crawled Time
09:00
2
10:00
1
11:00
1
13:00
1
14:00
1
14:20
1
14:30
1
15:00
1
15:30
1
19:00
1
21:00
2
Source
www.biospace.com
11
www.globenewswire.com
1
www.prnewswire.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Positive
symbols :
Azn
save search
ENHERTU® Granted Priority Review in the U.S. for Patients with Metastatic HER2 Positive Solid Tumors
Published:
2024-01-29
(Crawled : 11:00)
- biospace.com/
AZN
|
News
|
$70.54
0.59%
1.7M
|
Health Technology
|
4.52%
|
O:
0.24%
H:
0.07%
C:
-0.1%
enhertu
her2
granted
review
tumors
positive
AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data
Published:
2023-12-12
(Crawled : 15:30)
- biospace.com/
AZNCF
|
News
|
$138.73
3.7K
|
Health Technology
|
10.81%
|
O:
5.03%
H:
0.0%
C:
-3.82%
ICVX
|
$15.31
-0.65%
9.3M
|
|
50.64%
|
O:
53.48%
H:
1.02%
C:
0.26%
AZN
|
News
|
$70.54
0.59%
1.7M
|
Health Technology
|
10.44%
|
O:
1.54%
H:
0.06%
C:
-0.78%
vaccine
astrazeneca
positive
acquire
rsv
potential
Genprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting
Published:
2023-05-25
(Crawled : 21:00)
- prnewswire.com
AZNCF
|
News
|
$138.73
3.7K
|
Health Technology
|
-4.5%
|
O:
-0.47%
H:
0.0%
C:
-0.02%
GNPX
|
$2.28
5.41%
11K
|
Health Technology
|
154.12%
|
O:
3.65%
H:
7.04%
C:
1.02%
AZN
|
News
|
$70.54
0.59%
1.7M
|
Health Technology
|
-2.31%
|
O:
1.06%
H:
0.48%
C:
-0.04%
reqorsa
lung
asco
positive
cancer
cell
meeting
trial
therapy
Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
Published:
2023-02-16
(Crawled : 14:00)
- globenewswire.com
AZNCF
|
News
|
$138.73
3.7K
|
Health Technology
|
-1.46%
|
O:
-2.87%
H:
0.88%
C:
0.88%
FBIO
|
$1.8
2.86%
34K
|
Health Technology
|
135.69%
|
O:
0.81%
H:
5.54%
C:
3.66%
AZN
|
News
|
$70.54
0.59%
1.7M
|
Health Technology
|
0.63%
|
O:
-2.65%
H:
1.22%
C:
0.16%
cibmtr
trial
positive
therapy
ENHERTU® Achieved Statistically Significant Overall Survival Reducing the Risk of Death by 36% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast03
Published:
2022-12-07
(Crawled : 15:00)
- biospace.com/
AZN
|
News
|
$70.54
0.59%
1.7M
|
Health Technology
|
2.29%
|
O:
0.45%
H:
0.64%
C:
-0.03%
enhertu
risk
breast
positive
cancer
her2-
her2
metastatic breast cancer
Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders
Published:
2022-11-08
(Crawled : 14:20)
- biospace.com/
AZNCF
|
News
|
$138.73
3.7K
|
Health Technology
|
15.4%
|
O:
2.49%
H:
0.0%
C:
-1.6%
FBIO
|
$1.8
2.86%
34K
|
Health Technology
|
109.11%
|
O:
0.0%
H:
4.76%
C:
-4.6%
ATXI
|
$0.1301
55K
|
Health Technology
|
-92.22%
|
O:
7.78%
H:
6.67%
C:
-7.78%
AZN
|
News
|
$70.54
0.59%
1.7M
|
Health Technology
|
14.78%
|
O:
0.2%
H:
0.96%
C:
0.18%
treatment
acquisition
system
therapeutics
positive
ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician’s Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cancer
Published:
2022-08-15
(Crawled : 09:00)
- biospace.com/
AZN
|
News
|
$70.54
0.59%
1.7M
|
Health Technology
|
5.24%
|
O:
0.92%
H:
0.22%
C:
-0.65%
enhertu
treatment
disease
trial
positive
cancer
her2-
her2
metastatic breast cancer
ENHERTU® Approved in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen
Published:
2022-05-05
(Crawled : 10:00)
- biospace.com/
AZN
|
News
|
$70.54
0.59%
1.7M
|
Health Technology
|
5.24%
|
O:
-1.35%
H:
0.4%
C:
-1.2%
enhertu
approved
positive
cancer
breast cancer
her2-
her2
metastatic breast cancer
Artelo Biosciences Reports Positive Pre-clinical Results for Lead Program in Cancer-Related Cachexia
Published:
2022-04-13
(Crawled : 13:00)
- biospace.com/
AZNCF
|
News
|
$138.73
3.7K
|
Health Technology
|
0.22%
|
O:
-3.19%
H:
3.22%
C:
0.54%
AZN
|
News
|
$70.54
0.59%
1.7M
|
Health Technology
|
2.22%
|
O:
-0.04%
H:
0.84%
C:
0.57%
ARTL
|
News
|
$1.3004
14K
|
Health Technology
|
209.52%
|
O:
38.1%
H:
27.29%
C:
-12.83%
pre-clinical
program
positive
art27.13
preclinical
cancer
ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen
Published:
2022-01-17
(Crawled : 09:00)
- biospace.com/
AZN
|
News
|
$70.54
0.59%
1.7M
|
Health Technology
|
Email alert
Add to watchlist
enhertu
granted
positive
cancer
breast cancer
her2-
her2
metastatic breast cancer
ENHERTU® Additional Analyses Further Reinforce Groundbreaking Efficacy in Patients with HER2 Positive Metastatic Breast Cancer
Published:
2021-12-09
(Crawled : 19:00)
- biospace.com/
AZN
|
News
|
$70.54
0.59%
1.7M
|
Health Technology
|
27.21%
|
O:
0.27%
H:
0.63%
C:
-0.58%
enhertu
positive
cancer
breast cancer
her2-
her2
metastatic breast cancer
DESTINY-Breast11 Neoadjuvant Phase 3 Trial of ENHERTU® Initiated in Patients with High-Risk HER2 Positive Early-Stage Breast Cancer
Published:
2021-11-30
(Crawled : 14:30)
- biospace.com/
AZN
|
News
|
$70.54
0.59%
1.7M
|
Health Technology
|
25.93%
|
O:
-0.7%
H:
0.0%
C:
0.0%
risk
trial
positive
cancer
phase 3
breast cancer
initiated
her2-
her2
TROPION-Breast01 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Published:
2021-11-18
(Crawled : 21:00)
- biospace.com/
AZN
|
News
|
$70.54
0.59%
1.7M
|
Health Technology
|
21.48%
|
O:
-1.46%
H:
0.33%
C:
-0.32%
positive
cancer
phase 3
breast cancer
trial
initiated
hormone
her2+
her2-
her2
metastatic breast cancer
Gainers vs Losers
88%
12%
Top 10 Gainers
MTTR
|
News
M
|
$4.595
164.08%
13M
|
AGBA
|
$2.355
88.4%
34M
|
Finance
EDBL
|
News
|
$6.75
79.52%
1.5M
|
CZOO
|
$8.77
75.75%
11M
|
MTC
|
$2.28
46.15%
2.6M
|
Technology Services
VNRX
|
$0.84
40.0%
2.6M
|
Health Technology
OPRT
|
News
|
$3.14
39.56%
7.6M
|
Finance
MLEC
|
$1.865
33.21%
2.4M
|
n/a
PALI
|
$6.37
29.21%
21M
|
Manufacturing
CMAX
|
$4.12
28.35%
65K
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.